1. Home
  2. Ãéá ôï ãéáôñü
  3. ÌåôáëëÜîåéò ôïõ HIV

ÌåôáëëÜîåéò ôïõ éïý HIV

Ïé ìåôáëëÜîåéò ôïõ éïý HIV ðñïêáëïýí áíôï÷Þ óå äéÜöïñá áíôéñåôñïúêÜ öÜñìáêá Þ êáé óå ïëüêëçñåò êáôçãïñßåò áíôéñåôñïúêþí öáñìÜêùí, áíÜëïãá ìå ôçí èÝóç óôçí ïðïßá åìöáíßæïíôáé ðÜíù óôï ãïíßäéï ôçò áíôßóôñïöçò ìåôáãñáöÜóçò.
Ïé ìåôáëëÜîåéò áðïêáëýðôïíôáé ìå ôï ãïíïôõðéêü Ýëåã÷ï ðïõ ãßíåôáé ðñéí ôçí Ýíáñîç ôçò èåñáðåßáò Þ ðñéí ôçí áëëáãÞ ôçò èåñáðåßáò.

Áí ãíùñßæåôå ôéò ìåôáëëÜîåéò, ìðïñåßôå íá ôéò åéóÜãåôå ìå ÊÅÖÁËÁÉÁ ãñÜììáôá (ôçí ìßá êÜôù áðü ôçí Üëëç) óôçí ðáñáêÜôù öüñìá áíÜëõóçò ìåôáëëÜîåùí, ãéá íá äåßôå óå ðïéá öÜñìáêá õðÜñ÷åé áíôï÷Þ:


HIVdb Program: Mutation List Analysis

Reverse Transcriptase Mutations:


Protease Mutations:


Integrase Mutations:


Output Analysis:
Mutation Comments
Mutation Scores


ANALYZE


Áðü ôï ðáñáêÜôù link ìðïñåßôå íá êáôåâÜóåôå üëç ôç ëßóôá ôùí ìåôáëëÜîåùí, üðùò äçìïóéåýèçêå ôåëåõôáßá áðü ôï STANFORD HIV DRUG RESISTANCE DATABASE

Major HIV-1 Drug Resistance Mutations
ÅíçìÝñùóç: 22-06-2013

+/-
ÌÜèå ôï status óïõ

Âñåò ôï ãéáôñü óïõ

ÐÜñå èåñáðåßá

¸ëåãîå ôï ééêü óïõ öïñôßï

Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

Twitter

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò